Clinical Trials Logo
  1. Home
  2. Meningioma
  3. NCT04109404
  4. Details
NCT04109404 Clinical Trial

Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin

Meningioma Clinical Trial

— MAP  

Official title:
Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin: Retrospective Study in Patients Followed at the CHRU of Brest

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04109404
Other study ID # 29BRC19.0030
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 25, 2019
Est. completion date June 1, 2019

Study information
Verified date September 2019
Source University Hospital, Brest
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of Brest

Description:

Retrospective study in CHRU of brest, the investigators selected patient with history of méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE essentially The investigators excluded patient with risk factor of meningioma added at hormonal treatment exposition The investigators discribe the caractéristique of patients: age, sex, duration of the treatment, the caractéristique of the meningioma: localization, grade, hormonal receptors, treatment by surgery or radiotherapy and changing after discontinuation of treatment

Recruitment information / eligibility
Status Completed
Enrollment 110
Est. completion date June 1, 2019
Est. primary completion date June 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- minimum 18 years

- medical follow up in CHRU of Brest

- treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE, PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL , oestroprogestogenic contraception

- meningioma after treatement by progestin or CYPROTERONE ACETATE

Exclusion Criteria:

- history ofbreast cancer

- history of cerebral radiotherapy

- history of neurofibromatosis

- meningioma before treatement by progestin or CYPROTERONE ACETATE

- minor patient

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Département de Nutrition - CHRU de Brest Brest

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

References & Publications (2)

Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien). 2015 Oct;157(10):1741-6. doi: 10.1007/s00701-015-2532-3. Epub 2015 Aug 12. — View Citation

S. Froelich, "Does cyproterone acetate promote multiple meningiomas?," 2009.

Outcome
Type Measure Description Time frame Safety issue
Primary Diagnosis of meningiomas caracteristics meningiomas caracteristics in patient treated with CYPROTERONE ACETATE or Progestin description 12 months
Secondary prescription status of progestogenic treatment indications, duration of treatment, name and type of treatment 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04081701 - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Phase 4
Recruiting NCT03631953 - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Completed NCT01811524 - The Etiology and Progression of Brain Tumors N/A
Completed NCT03648034 - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality N/A
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Recruiting NCT06014905 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma Phase 1
Not yet recruiting NCT04386642 - Tranexamic Acid Reduce Blood Loss in Meningioma Resection Phase 4
Active, not recruiting NCT04595786 - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection N/A
Active, not recruiting NCT04305470 - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma Phase 3
Completed NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
Not yet recruiting NCT02978677 - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas N/A
Active, not recruiting NCT02933736 - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Early Phase 1
Completed NCT02267928 - Information Presentation Formats N/A
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Active, not recruiting NCT03071874 - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Phase 2
Recruiting NCT05416567 - Embolization for Meningioma N/A

External Links